Tau kinase inhibitors protect hippocampal synapses despite of insoluble tau accumulation

Molecular and Cellular Neuroscience

Volumn 37, Issue 3, 2008, Pages 559-567

  Hinners, Ina ^a   Hill, Anika ^a   Otto, Ulrike ^a   Michalsky, Anke ^a   Mack, Till G A ^a   Striggow, Frank ^a  

^a KeyNeurotek Pharmaceuticals AG   (Germany)

Author keywords

Alzheimer's disease; Hyperphosphorylation; Model system; Neuroprotection; Pathomechanism

Indexed keywords

EPITOPE; LITHIUM CHLORIDE; NEUROPROTECTIVE AGENT; SRN 003 556; TAU PROTEIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN PROTECTION; BRAIN SLICE; CELL SWELLING; CONTROLLED STUDY; DYSTROPHY; HIPPOCAMPUS; NERVE CELL DEGENERATION; NERVE CELL LESION; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PYRAMIDAL NERVE CELL; RAT; SYNAPSE; TISSUE CULTURE;

ANIMALS; ANIMALS, NEWBORN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GREEN FLUORESCENT PROTEINS; HIPPOCAMPUS; NERVE DEGENERATION; NEUROFILAMENT PROTEINS; ORGAN CULTURE TECHNIQUES; ORGANIC CHEMICALS; PROTEIN KINASE INHIBITORS; RATS; RATS, WISTAR; SERINE; STATISTICS, NONPARAMETRIC; SYNAPSES; TAU PROTEINS; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 39649090958     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2007.12.004     Document Type: Article

References (38)

1. Augustinack J.C., Schneider A., Mandelkow E.M., and Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. (Berl.) 103 (2002) 26-35
2. Beirowski B., Adalbert R., Wagner D., Grumme D.S., Addicks K., Ribchester R.R., and Coleman M.P. The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (WldS) nerves. BMC Neurosci. 6 (2005) 6
3. Braak H., and Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging 16 (1995) 271-278 (discussion 278-284)
4. Braak E., Braak H., and Mandelkow E.M. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol. (Berl.) 87 (1994) 554-567
5. Braak H., Braak E., and Strothjohann M. Abnormally phosphorylated tau protein related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex of sheep and goat. Neurosci. Lett. 171 (1994) 1-4
6. Davies P. A very incomplete comprehensive theory of Alzheimer's disease. Ann. N.Y. Acad. Sci. 924 (2000) 8-16
7. Ferrari A., Hoerndli F., Baechi T., Nitsch R.M., and Gotz J. beta-Amyloid induces paired helical filament-like tau filaments in tissue culture. J. Biol. Chem. 278 (2003) 40162-40168
8. Forman M.S., Trojanowski J.Q., and Lee V.M. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 10 (2004) 1055-1063
9. Gotz J., Chen F., van Dorpe J., and Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293 (2001) 1491-1495
10. Gotz J., Deters N., Doldissen A., Bokhari L., Ke Y., Wiesner A., Schonrock N., and Ittner L.M. A decade of tau transgenic animal models, beyond. Brain Pathol. 17 (2007) 91-103
11. Hasegawa M., Jakes R., Crowther R.A., Lee V.M., Ihara Y., and Goedert M. Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Lett. 384 (1996) 25-30
12. Ingelsson M., Fukumoto H., Newell K.L., Growdon J.H., Hedley-Whyte E.T., Frosch M.P., Albert M.S., Hyman B.T., and Irizarry M.C. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62 (2004) 925-931
13. Kosik K.S., and Shimura H. Phosphorylated tau and the neurodegenerative foldopathies. Biochim. Biophys. Acta 1739 (2005) 298-310
14. LaFerla F.M., and Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol. Med. 11 (2005) 170-176
15. Le Corre S., Klafki H.W., Plesnila N., Hubinger G., Obermeier A., Sahagun H., Monse B., Seneci P., Lewis J., Eriksen J., Zehr C., Yue M., McGowan E., Dickson D.W., Hutton M., and Roder H.M. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 9673-9678
16. Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Paul Murphy M., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W.L., Yen S.H., Dickson D.W., Davies P., and Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25 (2000) 402-405
17. Lim J., and Lu K.P. Pinning down phosphorylated tau and tauopathies. Biochim. Biophys. Acta 1739 (2005) 311-322
18. Lippa C.F. Synaptophysin immunoreactivity in Pick's disease: comparison with Alzheimer's disease and dementia with Lewy bodies. Am. J. Alzheimer's Dis. Other Dement. 19 (2004) 341-344
19. Lovestone S., Davis D.R., Webster M.T., Kaech S., Brion J.P., Matus A., and Anderton B.H. Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations. Biol. Psychiatry 45 (1999) 995-1003
20. Lu P.J., Wulf G., Zhou X.Z., Davies P., and Lu K.P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 399 (1999) 784-788
21. Mack T.G., Dayanandan R., Van Slegtenhorst M., Whone A., Hutton M., Lovestone S., and Anderton B.H. Tau proteins with frontotemporal dementia-17 mutations have both altered expression levels and phosphorylation profiles in differentiated neuroblastoma cells. Neuroscience 108 (2001) 701-712
22. Mandelkow E.M., and Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol. 8 (1998) 425-427
23. Oddo S., Caccamo A., Tran L., Lambert M.P., Glabe C.G., Klein W.L., and LaFerla F.M. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J. Biol. Chem. 281 (2006) 1599-1604
24. Ramsden M., Kotilinek L., Forster C., Paulson J., McGowan E., SantaCruz K., Guimaraes A., Yue M., Lewis J., Carlson G., Hutton M., and Ashe K.H. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci. 25 (2005) 10637-10647
25. Reddy P.H., Mani G., Park B.S., Jacques J., Murdoch G., Whetsell Jr. W., Kaye J., and Manczak M. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J. Alzheimer's Dis. 7 (2005) 103-117 (discussion 173-180)
26. Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., and Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309 (2005) 476-481
27. Sergeant N., Bussiere T., Vermersch P., Lejeune J.P., and Delacourte A. Isoelectric point differentiates PHF-tau from biopsy-derived human brain tau proteins. NeuroReport 6 (1995) 2217-2220
28. Sergeant N., Delacourte A., and Buee L. Tau protein as a differential biomarker of tauopathies. Biochim. Biophys. Acta 1739 (2005) 179-197
29. Shahani N., Subramaniam S., Wolf T., Tackenberg C., and Brandt R. Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices. J. Neurosci. 26 (2006) 6103-6114
30. Spires T.L., and Hyman B.T. Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2 (2005) 423-437
31. Spires T.L., Orne J.D., SantaCruz K., Pitstick R., Carlson G.A., Ashe K.H., and Hyman B.T. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am. J. Pathol. 168 (2006) 1598-1607
32. Stoppini L., Buchs P.A., and Muller D. A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods 37 (1991) 173-182
33. Ulfig N., Nickel J., and Bohl J. Monoclonal antibodies SMI 311 and SMI 312 as tools to investigate the maturation of nerve cells and axonal patterns in human fetal brain. Cell Tissue Res. 291 (1998) 433-443
34. Vincent I., Zheng J.H., Dickson D.W., Kress Y., and Davies P. Mitotic phosphoepitopes precede paired helical filaments in Alzheimer's disease. Neurobiol. Aging 19 (1998) 287-296
35. Xie H., Litersky J.M., Hartigan J.A., Jope R.S., and Johnson G.V. The interrelationship between selective tau phosphorylation and microtubule association. Brain Res. 798 (1998) 173-183
36. Yoshiyama Y., Higuchi M., Zhang B., Huang S.M., Iwata N., Saido T.C., Maeda J., Suhara T., Trojanowski J.Q., and Lee V.M. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53 (2007) 337-351
37. Zhao L., Ma Q.L., Calon F., Harris-White M.E., Yang F., Lim G.P., Morihara T., Ubeda O.J., Ambegaokar S., Hansen J.E., Weisbart R.H., Teter B., Frautschy S.A., and Cole G.M. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci. 9 (2006) 234-242
38. Zhukareva V., Shah K., Uryu K., Braak H., Del Tredici K., Sundarraj S., Clark C., Trojanowski J.Q., and Lee V.M. Biochemical analysis of tau proteins in argyrophilic grain disease, Alzheimer's disease, and Pick's disease: a comparative study. Am. J. Pathol. 161 (2002) 1135-1141